Chief Sales Officer of AI-Media Excited to Showcase Subtitling Innovation at Upcoming IBC Broadcast Tradeshow

AI-Media Exhibits at IBC 2023

AI-Media to exhibit at IBC 2023 in Amsterdam, NE from 15-18 Sept 2023

BROOKLYN, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — AI-Media, the leader in technology-driven live captioning & subtitling, transcription, and translation solutions, is excited to announce its presence at the IBC Show 2023, scheduled to take place from 15th – 18th September in Amsterdam, NE. The event promises to be a gathering of industry experts, thought leaders, and innovative companies in the broadcast and media technology sector.

As the global leader in captioning and subtitling for the broadcast industry, AI-Media is proud to be part of this influential event. Our Chief Sales Officer, James Ward, will lead our delegation and represent our commitment to excellence in delivering cutting-edge solutions to our clients and partners.

AI-Media’s Chief Sales Officer, James Ward said:

“We are delighted to participate at the IBC show once again. This tradeshow is an exceptional platform for us to showcase our latest innovations and demonstrate how we continue to push the boundaries of what’s possible in the broadcast industry. We’re excited to engage with industry leaders, customers, and partners, and to share our vision for the future of broadcasting.”

AI-Media will be showcasing several key broadcast solutions at the event, the cornerstone of which is our AI-Powered live automatic captioning solution – LEXI. LEXI consistently delivers accuracy rates of over 98%, identifies speaker changes, uses AI to ensure captions don’t interrupt onscreen content and all at a fraction of the cost of human captions. This innovative tool is revolutionizing real-time captioning, providing a cost-effective solution that has been embraced by the world’s leading broadcasters. AI-Media will be conducting live demos at the booth to display this groundbreaking technology in action.

The recently launched AI-powered LEXI Captioning Tool Kit will also be featured at IBC2023, featuring six key solutions each designed to address different captioning needs. LEXI Tool Kit transforms content creation and captioning, offering complete end-to-end solutions for media companies, broadcasters, event producers, educational institutions, and content creators worldwide. Broadcasters can mix and match the Tool Kit components to suit their business needs, accessing solutions including captioning, translation, archiving & search and disaster recovery.

With IP video production at the forefront of innovation in the broadcasting landscape; broadcasters can look to AI-Media’s ALTA solution for their IP compatible closed captioning and subtitling encoding solution. ALTA supports global broadcast standards including SMPTE-2110, MPEG-TS inputs, and can output 2110-40, DVB subtitles, DVB TTML, DVB Teletext and SMPTE 2038. Deployable as a standalone virtual machine, a pre-packaged AMI or turnkey physical server, ALTA can fit into any production workflow. Along with effortlessly handling six languages per instance, ALTA also supports the insertion of advertising cues using SCTE-35 and SCTE-104. With ALTA, AI-Media is helping broadcasters elevate their IP video broadcasts to new heights of reach and accessibility. Also available at the booth will be our range of SDI Hardware Encoders, including our Encoder Pro (HD492) 1 RU caption encoder – now synonymous as the broadcast standard for SDI encoders.

We’re also excited to provide customers with an early look at our upgraded LEXI Translate solution, which is the next level of language accessibility within our LEXI Tool Kit. This soon to be released version boasts unmatched accuracy in real-time translation, allowing broadcasters to distribute content to a wider audience than ever before.

Join AI-Media at IBC 2023, September 15-18, RAI Amsterdam Convention Centre, Booth #5.C31. Attendees are encouraged to book a meeting with the AI-Media team to discover our range of end-to-end broadcast captioning solutions.

About AI-Media

Founded in Australia in 2003, technology company AI-Media is a global leader in live and recorded captioning, transcription and translation solutions. The company helps the world’s leading broadcasters, enterprises and government agencies ensure high accuracy, secure and cost-effective captioning via its AI-powered LEXI automatic captioning solution. LEXI captions are delivered to millions of screens worldwide via AI-Media’s range of captioning encoders and its iCap Cloud Network – the world’s largest, most secure caption delivery network. Globally, AI-Media delivers over 8 million minutes of live and recorded media monthly. AI-Media trades on the Australian Stock Exchange (ASX:AIM). For more information, please visit AI-Media.tv.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/976356bd-2ae1-4f56-89ed-437f9da454a2

Media Contact:
Fiona Habben
Senior Marketing Manager – Global
Fiona.habben@ai-media.tv

GlobeNewswire Distribution ID 8921516

A Curia apoia o ensaio clínico de fase 1 da nova vacina de RNA de última geração da Replicate Bioscience

O fornecimento de um fármaco fabricado segundo as normas de BPFa apoia o primeiro estudo clínico em seres humanos do novo RNA autorreplicante (srRNA) RBI-4000

ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato, anunciou hoje que sua parceira, Replicate Bioscience, recebeu autorização IND da FDA e dosou o primeiro participante com RBI-4000, uma vacina autorreplicante (de srRNA) contra a raiva, em um estudo clínico de fase 1 utilizando material clínico desenvolvido como parte da colaboração com a Curia.

A Curia liderou o desenvolvimento do processo, o aumento de escala e a fabricação de acordo com as BPFa do fármaco de srRNA RBI-4000. Com aproximadamente 10.000 bases, este srRNA é significativamente maior do que um RNAm linear convencional e, historicamente, tem sido difícil fabricá-lo nas escalas necessárias para o desenvolvimento clínico. O desenvolvimento do método analítico da Curia e a qualificação dos ensaios também foram fundamentais para a liberação dessa molécula de srRNA.

“A Curia se orgulha de ser pioneira na fabricação dessa nova classe de tecnologia de srRNA ao fornecer o fármaco de srRNA RBI-4000 à nossa parceira Replicate para apoiar seu ensaio clínico de fase 1”, afirmou Christopher Conway, Presidente de Pesquisa e Desenvolvimento da Curia. “Dedicamo-nos a fornecer soluções vantajosas, desde o desenvolvimento até a fabricação de acordo com as BPFa para nossos clientes na área de RNAm.”

Essa nova classe de vacinas de srRNA trazem várias vantagens em relação às vacinas de RNAm existentes, incluindo a necessidade de dosagens mais baixas e maior tolerabilidade. Esse avanço abre também a porta a mais inovações em RNA para uso em vacinas e terapias com menos restrições em relação ao tamanho das moléculas.

“Nossa colaboração com a Curia nos ajudou a fabricar uma nova classe de RNAs autorreplicantes que têm o potencial de fornecer perfis melhorados de bioatividade, tolerabilidade e eficácia em comparação com outras tecnologias de RNA”, disse Nathaniel Wang, PhD., fundador e CEO da Replicate. “A Curia ampliou a escala de um processo para RNAs mais longos, que permitiu a produção em larga escala com rendimentos, pureza e potência suficientes para apoiar o ensaio clínico de fase 1 da Replicate.”

A Curia está comprometida em ser uma parceira preferencial desde a descoberta e desenvolvimento até à fabricação e comercialização, fornecendo um conjunto completo de serviços de suporte a pequenas e grandes moléculas, fármacos, enchimento e acabamento asséptico de produtos farmacêuticos e testes laboratoriais em todas as fases do ciclo de vida do desenvolvimento de medicamentos.

Sobre a Curia
A Curia, antiga AMRI, é uma organização líder em pesquisa, desenvolvimento e fabricação por contrato, que fornece produtos e serviços desde a P&D até a fabricação em escala comercial para clientes farmacêuticos e biofarmacêuticos. Os quase 4.000 funcionários da Curia em 29 locais nos Estados Unidos, Europa e Ásia ajudam seus clientes a progredir da curiosidade à cura. Saiba mais em CuriaGlobal.com.

Informações de contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8921444

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)

ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with RBI-4000, a self-replicating (srRNA) rabies vaccine, in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

Curia conducted process development, scale-up and cGMP manufacture of srRNA RBI-4000 drug substance. At approximately 10,000 bases, this srRNA is significantly larger than a conventional linear mRNA and has been historically difficult to manufacture at the scales required for clinical development. Curia’s analytical method development and qualification of the assays were also critical to the release of this srRNA molecule.

“Curia is proud to be a pioneer in manufacturing this new class of srRNA technology by delivering RBI-4000 srRNA drug substance to our partner Replicate in support of their Phase 1 clinical trial,” said Christopher Conway, President, Research & Development, Curia. “We are dedicated to providing advantaged solutions from development to cGMP manufacture for our customers in the mRNA field.”

This new class of srRNA vaccine offers a number of potential improvements to existing mRNA vaccines, including lower dosage requirements and improved tolerability. The advancement also opens the door for further RNA innovation for use in vaccines and therapeutics with fewer constraints on molecule size.

“Our collaboration with Curia helped us manufacture a new class of self-replicating RNAs which have the potential to deliver improved bioactivity, tolerability and efficacy profiles as compared to other RNA technologies,” said Nathaniel Wang, Ph.D., founder and CEO of Replicate. “Curia scaled up a process for longer RNAs that enabled large-scale production at yields, purity and potency to support Replicate’s Phase 1 clinical trial.”

Curia is committed to being a partner of choice from discovery and development through manufacture and commercialization, providing a full suite of services to support small and large molecule, drug substance, drug product aseptic fill-finish and laboratory testing at every phase of the drug development life cycle.

About Curia
Curia, formerly AMRI, is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8920285

Curia soutient l’essai clinique de phase 1 de Replicate Bioscience sur un vaccin novateur à base d’ARN de nouvelle génération

L’entreprise apporte une substance médicamenteuse fabriquée selon les BPFa afin de permettre la première étude clinique chez un être humain du nouvel ARN auto-répliquant (ARNar) RBI-4000

ALBANY, ÉTAT DE NEW YORK, 13 sept. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, développement et fabrication en sous-traitance de premier plan, a annoncé aujourd’hui que son partenaire, Replicate Bioscience, a reçu une autorisation de sa demande de nouveau médicament expérimental (Investigational New Drug, IND) auprès de la FDA et a dosé le premier participant avec RBI-4000, un vaccin antirabique à base d’ARN auto-répliquant (ARNar) pour une étude clinique de phase 1 employant du matériel clinique développé dans le cadre de sa collaboration avec Curia.

Curia a mené le développement des procédés, la mise à l’échelle et la fabrication respectant les BPFa de la substance médicamenteuse à base d’ARNar RBI-4000. Comptant environ 10 000 bases, cet ARNar est bien plus grand qu’un ARNm linéaire conventionnel et a toujours été difficile à fabriquer aux échelles requises pour le développement clinique. Le développement d’une méthode analytique par Curia et la qualification des essais ont aussi joué un rôle crucial dans le lancement de cette molécule d’ARNar.

« Curia est fière d’être une pionnière dans la fabrication de cette nouvelle classe de technologie d’ARNar en fournissant la substance médicamenteuse à base d’ARNar RBI-4000 à son partenaire Replicate afin de soutenir son essai clinique de phase 1 », a déclaré Christopher Conway, président de la recherche et du développement chez Curia. « Nous nous dédions à offrir des solutions avantageuses, depuis le développement jusqu’à une fabrication respectant les BPFa, à nos clients dans le domaine de l’ARNm. »

Cette nouvelle classe d’ARNar apporte de nombreuses améliorations potentielles aux vaccins existants à base d’ARNm, notamment des posologies plus basses et une meilleure tolérance. Cet avancement ouvre également la voie à une innovation supplémentaire de l’ARN en vue d’une utilisation dans les vaccins et produits thérapeutiques avec moins de contraintes en ce qui concerne la taille des molécules.

« Notre collaboration avec Curia nous a aidés à fabriquer une nouvelle classe d’ARN auto-répliquants qui ont le potentiel d’offrir des profils de bio-activité, de tolérance et d’efficacité améliorés en comparaison avec les autres technologies d’ARN », a commenté Nathaniel Wang, Ph.D., fondateur et PDG de Replicate. « Curia a élaboré un processus pour des ARN plus longs ayant permis une production à grande échelle selon des rendements, une pureté et une puissance à même de soutenir l’essai clinique de phase 1 de Replicate. »

Curia est déterminée à être un partenaire de choix depuis la découverte et le développement jusqu’à la fabrication et la commercialisation, en fournissant une suite complète de services permettant la prise en charge des activités de remplissage-finition aseptique des produits médicamenteux, substances médicamenteuses, petites et grandes molécules, ainsi que des tests en laboratoire, à chaque phase du cycle de vie du développement de médicaments.

À propos de Curia
Curia, anciennement AMRI, est une organisation de recherche, développement et fabrication en sous-traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Basés sur 29 sites à travers les États-Unis, l’Europe et l’Asie, les près de 4 000 employés de Curia aident les clients de l’entreprise à passer de la curiosité à la guérison. Pour en savoir plus, rendez-vous sur CuriaGlobal.com.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8921444

Annual Investment Meeting announces new identity as AIM Congress, gears up for 13th edition in Abu Dhabi, May 2024

ABU DHABI, United Arab Emirates, Sept. 13, 2023 (GLOBE NEWSWIRE) — Under its new identity as “AIM Congress,” the Organizing Committee of the World’s Leading Investment Platform will once again gather together regional and international leaders, thinkers, and innovators at the 13th edition of the event taking place from 7 to 9 May 2024 at the Abu Dhabi National Exhibition Centre.

To be anchored on the theme “Adapting to a Shifting Investment Landscape: Harnessing New Potential for Global Economic Development,” AIM Congress 2024 is supported by the Ministry of Industry and Advanced Technology and the Abu Dhabi Department of Economic Development (ADDED) as lead partner.

To be hosted again in the UAE’s vibrant capital, AIM Congress 2024 plans to surpass the success achieved by its last year’s edition which attracted 10,313 participants and 693 speakers from 175 countries.

His Excellency Dr. Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade, expressed his enthusiasm for AIM Congress 2024, stating that, “For more than a decade, AIM Congress has been steadfast in its commitment to promote global economic cooperation and harness the potential of countries especially emerging markets. Amid the backdrop of the shifting global investment scene, it is all-important for countries to adapt and explore new avenues for growth. For its 2024 edition, AIM Congress will continue to be the leading venue where the world’s key economic stakeholders congregate to facilitate dialogue and pave the way for impactful investments that propel a brighter, better future for each and everyone.”

His Excellency Ahmed Jasim Al Zaabi, Chairman of ADDED, said: “Building on the remarkable success of AIM’s previous edition, we are raising the bar to meet the expectations of the global investment community. As the Capital of Capital, Abu Dhabi is leading global conversations on investments outlook and dynamics in an era characterised by mega shifts. Our approach to inward and outward investments is guided by our unwavering commitment to place human development, sustainability, and advanced technology at the core of socio-economic plans at local and international levels, support of ESG agendas, and enhance synergies through international cooperation to improve life for all.”

For his part, Dawood Al Shezawi, President of AIM Global Foundation, commented: “In the face of the various challenges confronting our world today, coupled with the continued decline in global economic growth, emerges the announcement of AIM’s new identity as AIM Congress, which positions itself as a premier venue for investment, providing the optimal platform for esteemed leaders and decision-makers around the world to collectively address our most pressing issues, reshape the global trade and investment landscape, and ultimately foster positive, enduring social and economic impacts in diverse regions worldwide.”

AIM Congress is built upon a foundation of its five key pillars – FDI, FPI, Startups, SMEs, and Future Cities – that underpin the event’s objectives and provide a framework for its activities.

For more details
Shreya Verma – +971 521133926
shreya.verma@aimcongress.com

GlobeNewswire Distribution ID 1000839289

Deriv Group to launch Deriv Prime at IFX EXPO Cyprus 2023

Deriv Prime – Liquidity solution provider

Deriv Prime – Global Liquidity for All

LIMASSOL, Cyprus, Sept. 13, 2023 (GLOBE NEWSWIRE) — Deriv Group has announced that it will launch its institutional arm, Deriv Prime, at the upcoming IFX Expo in Limassol, Cyprus, from the 19th to the 21st of September 2023.

The venture aims to reshape the landscape of liquidity access and trading dynamics by offering comprehensive liquidity solutions to meet the needs of brokerage firms, corporations, startups, and other financial entities, regardless of their business scale.

Deriv Prime marks an advancement in institutional liquidity solutions, presenting a compelling proposition for institutions seeking to navigate the complex trading world. With its cutting-edge technology, extensive network, and institutional-centric approach, Deriv Prime addresses liquidity needs and ushers in a new era of trading possibilities. This disruption could spark a broader trend of reimagining liquidity solutions, ultimately fostering a more dynamic and competitive environment.

Deriv Prime’s ecosystem is underpinned by cutting-edge technology, delivering seamless operations with minimal latency or disruptions. This infrastructure boasts several key features: effortless integration with existing systems, ultra-low latency facilitated by intelligent order routing, reliable access to deep liquidity pools for competitive price feeds, and dedicated support.

“Deriv Prime doesn’t just provide liquidity. It’s a strategic response to the challenges faced by institutions in today’s ever-changing financial landscape,” said Alexandros A. Patsalides, Head of Deriv Prime.

“Deriv Prime accommodates top-of-book liquidity and unparalleled market depth. This adaptability ensures that a broad spectrum of traders can find suitable options within the Deriv Prime ecosystem,” continues Patsalides.

Deriv Prime integration is highlighted for its simplicity, facilitated by FIX protocol that seamlessly links a user’s bridge provider or MT5 gateway. With an average execution speed under 50ms, orders are intelligently routed, ensuring enhanced liquidity and efficiency.

As brokers expand to new markets, portfolio diversification is no longer an option to cater to the needs of different traders. Deriv Prime rises to meet this demand, offering diverse assets that include Forex, Cryptocurrencies, Commodities, Stocks and Indices, and ETFs that can be customised to suit the distinct trading needs of brokers and their clients.

About Deriv

Starting its journey in 1999, Deriv’s mission has been to make online trading accessible to anyone, anywhere. Deriv’s product offering includes intuitive trading platforms, over 200 tradable assets (in markets such as forex, stocks, and cryptocurrencies), unique trade types, and more. With more than 1,200 employees in 20 global offices spread across 16 countries, Deriv strives to provide the best work environment, which includes positive work culture, timely addressing of employee concerns, celebrating achievements, and conducting initiatives to boost their morale.

PRESS CONTACT
Aleksandra Zuzic
aleksandra@deriv.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/271135a6-6104-4c25-9256-3f926a0d043b

GlobeNewswire Distribution ID 1000839274